Details of the Drug
General Information of Drug (ID: DMFNB40)
Drug Name |
Noradrenalone (arterenone)
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Arterenone; 499-61-6; Noradrenalone; 2-Amino-1-(3,4-dihydroxyphenyl)ethanone; 2-Amino-1-(3,4-dihydroxyphenyl)ethan-1-one; Arterenon; EINECS 207-883-3; U 0603; 2-Amino-3',4'-dihydroxyacetophenone; BRN 2719260; Ethanone, 2-amino-1-(3,4-dihydroxyphenyl)-; ACETOPHENONE, 2-AMINO-3',4'-DIHYDROXY-; ADROLOP; AC1Q5DI7; SCHEMBL1703207; AC1L1V18; CTK4J1837; 5090-29-9 (hydrochloride); DTXSID10198144; MolPort-001-785-861; ZINC37629258; AKOS006275024; ACN-049173; AS07040; LS-13364; KB-282798; KB-227300; Ethanone,2-amino-1-(3,4-dihydroxyphenyl)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 167.16 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||